Verastem (VSTM) Given Consensus Rating of “Buy” by Brokerages

Shares of Verastem (NASDAQ:VSTM) have earned a consensus rating of “Buy” from the eleven research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $10.94.

A number of analysts recently weighed in on the stock. Cantor Fitzgerald reissued a “buy” rating and issued a $17.00 target price on shares of Verastem in a research note on Tuesday, March 13th. B. Riley assumed coverage on shares of Verastem in a research note on Thursday, March 8th. They issued a “buy” rating and a $15.00 target price on the stock. Zacks Investment Research raised shares of Verastem from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. HC Wainwright set a $10.00 target price on shares of Verastem and gave the company a “buy” rating in a research note on Wednesday, December 13th. Finally, Oppenheimer set a $13.00 target price on shares of Verastem and gave the company a “buy” rating in a research note on Thursday, December 21st.

How to Become a New Pot Stock Millionaire

NASDAQ VSTM opened at $2.98 on Friday. The stock has a market capitalization of $151.39, a P/E ratio of -1.69 and a beta of 2.25. Verastem has a twelve month low of $1.61 and a twelve month high of $5.71. The company has a current ratio of 5.13, a quick ratio of 5.13 and a debt-to-equity ratio of 0.26.

Verastem (NASDAQ:VSTM) last posted its earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.01). research analysts anticipate that Verastem will post -1.45 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in Verastem by 10.3% during the second quarter. Vanguard Group Inc. now owns 1,143,642 shares of the biopharmaceutical company’s stock worth $2,493,000 after buying an additional 107,029 shares during the last quarter. Artal Group S.A. grew its stake in Verastem by 33.3% during the fourth quarter. Artal Group S.A. now owns 1,000,000 shares of the biopharmaceutical company’s stock worth $3,070,000 after buying an additional 250,000 shares during the last quarter. Citadel Advisors LLC bought a new stake in Verastem during the third quarter worth about $195,000. Monashee Investment Management LLC bought a new stake in Verastem during the fourth quarter worth about $844,000. Finally, Point72 Asset Management L.P. bought a new stake in Verastem during the third quarter worth about $6,580,000. 31.65% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was posted by WKRB News and is the property of of WKRB News. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.wkrb13.com/2018/04/01/verastem-vstm-given-consensus-rating-of-buy-by-brokerages.html.

Verastem Company Profile

Verastem, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company's lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.

Analyst Recommendations for Verastem (NASDAQ:VSTM)

Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply